B40.2 Pulmonary blastomycosis, unspecified

Name of the Condition

• Pulmonary blastomycosis, unspecified

Summary

Pulmonary blastomycosis, unspecified is a fungal infection of the lungs caused by Blastomyces dermatitidis (and related species). It results from inhaling airborne spores of the fungus, which convert to yeast in the lungs and may cause localized or systemic disease. The condition may present with respiratory symptoms and can progress to severe illness, particularly in immunocompromised individuals. The term "unspecified" indicates that the clinical documentation does not specify whether the infection is acute or chronic.

Causes

The infection is caused by inhaling spores of Blastomyces fungi, which are found in soil and decaying organic matter (e.g., wood, leaves) in endemic regions. The spores germinate in the lungs, where they multiply and may spread hematogenously to other organs, including the skin, bones, and central nervous system. Direct inoculation (e.g., through skin wounds) is rare.

Risk Factors

• Residence in or travel to endemic areas (e.g., parts of North America, particularly the Ohio and Mississippi River valleys).
• Occupational or recreational exposure to soil (e.g., construction, forestry, gardening).
• Immunocompromised states (e.g., HIV/AIDS, organ transplantation, chronic steroid use).
• Male gender (higher incidence reported).
• Advanced age.

Symptoms

• Pulmonary: Cough (productive or non-productive), chest pain, dyspnea, fever, night sweats, weight loss.
• Systemic: Fatigue, myalgia, arthralgia.
• Disseminated disease may involve skin, bones, or central nervous system.

Diagnosis

Diagnosis typically involves a combination of clinical evaluation, imaging studies (e.g., chest X-ray or CT), and laboratory testing. Sputum or tissue samples may be examined for fungal elements, cultured for Blastomyces, or tested via molecular methods (e.g., PCR). Biopsy of affected tissues may be performed to confirm invasive disease. Serologic tests are available but may have limitations in sensitivity and specificity.

Treatment Options

Treatment generally involves antifungal medications, such as itraconazole for mild to moderate disease or amphotericin B for severe or disseminated cases. The duration of therapy depends on the severity and extent of infection, typically ranging from several months to a year. Close monitoring for treatment response and potential side effects is essential.

Prognosis and Follow-Up

Prognosis varies based on the severity of infection, host immune status, and timeliness of treatment. Most patients with mild to moderate disease respond well to antifungal therapy, while severe or disseminated cases may have higher morbidity. Follow-up includes clinical assessment, imaging, and laboratory testing to monitor for resolution or recurrence. Immunocompromised individuals may require longer treatment and more frequent monitoring.

Complications

Potential complications include respiratory failure, acute respiratory distress syndrome (ARDS), dissemination to other organs (e.g., skin, bones, central nervous system), and chronic lung damage. Delayed diagnosis or inadequate treatment can increase the risk of severe outcomes, particularly in immunocompromised patients.

Lifestyle & Prevention

• Avoid exposure to soil or decaying organic matter in endemic areas, especially during activities like gardening or construction.
• Wear protective equipment (e.g., masks) when working in high-risk environments.
• Promptly seek medical evaluation for respiratory symptoms if exposure to endemic regions is suspected.
• Maintain overall health to support immune function.

When to Seek Professional Help

Seek immediate medical attention if you experience persistent or worsening respiratory symptoms (e.g., cough, chest pain, difficulty breathing), fever, or unexplained weight loss, especially if you live in or have traveled to an endemic area. Immunocompromised individuals should be particularly vigilant and consult a healthcare provider at the onset of any concerning symptoms.

Tips for Medical Coders

When coding pulmonary blastomycosis, unspecified (B40.2), ensure the documentation supports the absence of specification for acute or chronic presentation. Verify that the diagnosis aligns with clinical findings and that no additional details (e.g., acute or chronic) are documented, which would require a more specific code. Confirm that the code is used for pulmonary involvement without systemic dissemination, as other codes may apply if extrapulmonary sites are involved.